GlassScriptPhysician profile
Aurora C Mariani
NPI 1184700353
$4,032.14
in general payments reported to CMS, 2019-2025
29 companies · $1,229 in 2025
The $1,229 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $309 · 2021: $743 · 2022: $484 · 2023: $379 · 2024: $747 · 2025: $1,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,355.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $750.35 | 2020-2025 | Breztri, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $584.53 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $553.39 | 2020-2025 | Krystexxa, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $382.16 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.30 | 2023-2025 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $184.49 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $147.78 | 2021-2023 | |
| Ani Pharmaceuticals, INC. | $138.19 | 2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $132.96 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $131.52 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $127.06 | 2023-2024 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $93.68 | 2021-2022 | |
| Abbott Laboratories | $89.50 | 2021-2024 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $72.85 | 2021-2023 | Krystexxa |
| Pfizer INC. | $70.88 | 2020-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $58.71 | 2022-2023 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $56.82 | 2021 | |
| Insmed, INC. | $50.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $36.78 | 2023-2024 | Camzyos, Eliquis |
| Corcept Therapeutics | $25.69 | 2024 | Korlym |
| Insulet Corporation | $22.44 | 2024 | Omnipod |
| Merck Sharp & Dohme LLC | $20.00 | 2019 | |
| Abbvie INC. | $19.50 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.44 | 2025 | Rexulti |
| Organogenesis INC. | $16.51 | 2019 | |
| Irhythm Technologies, INC. | $16.45 | 2022 | |
| Vifor Pharma, INC. | $15.37 | 2021 | |
| Astellas Pharma US INC | $15.22 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aurora Mariani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.